BGG and its subsidiary, Algae Health Sciences, Inc., will have a greater capacity in their glass tube photoreactor microalgae farm to support a growth in production.
“We’ve seen outstanding increases in our astaxanthin business in recent years as brand owners around the world have come to understand BGG’s value proposition and our unsurpassed quality astaxanthin,” Chunhua Li, founder and chairman of BGG world, said. “And discerning brands really appreciate that we back up our product quality with human clinical research. In fact, we published three peer-reviewed clinical trials on our AstraZine natural astaxanthin last year alone to support our customers’ marketing and to further the science and public awareness of the health benefits of this wonderful, health-giving molecule.”
The first stage of this expansion is already underway, with the farm’s current footprint growing through the acquisition of additional glass tubing. This will increase the current capacity by 25% in the third quarter of 2020. Additionally, the farm also plans to purchase and expand upon land directly adjacent to it by the end of the first quarter of 2021.
“With this new round of investment in our farm, we will secure enough production capacity to support our growth for the next few years and to position BGG as the leading producer worldwide,” Li said.